Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1722 of 6351
-
Could a lower dose of this antibody tame Slow-Growing lymphoma?
Disease control Recruiting nowThis phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could the gut microbiome hold clues to eating disorder recovery?
Knowledge-focused Recruiting nowThe goal of this observational study is to learn if behavioral and psychological factors are associated with the intestinal microbiota composition and function in children and adolescents with eating disorders (ED). The main questions it aims to answer are: * Are there any diffe…
Sponsor: Esther Nova • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
New drug shows promise for Crohn's sufferers in Mid-Stage trial
Disease control OngoingThis is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
New drug aims to supercharge immune system against tough cancers
Disease control Recruiting nowStudy QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human…
Phase 1 • Sponsor: Nammi Therapeutics Inc • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo aims to shrink lung tumors in early trial
Disease control OngoingPurpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New combo pill could tame stubborn diabetes
Disease control CompletedPhase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.
Phase 3 • Sponsor: Celltrion • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a One-Week radiation blast beat three weeks for breast cancer?
Disease control Recruiting nowIn breast cancer patients with nodal involvement, numerous studies have demonstrated that adjuvant radiation therapy reduces the risk of local recurrence, regional recurrence, and distant metastases, in addition to improving survival. The dose and fractionation for adjuvant breas…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New psoriasis pill shows promise in Mid-Stage trial
Symptom relief CompletedTo assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis, as well as the PK and PD characteristics of multiple doses
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy injection aims to restore sight in rare eye diseases
Disease control OngoingA Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal inj…
Phase 1 • Sponsor: Ray Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could lavender oil ease PTSD? new trial aims to find out
Symptom relief Recruiting nowPosttraumatic stress disorder (PTSD) is a common and debilitating mental illness. Current treatments for PTSD include psychotherapy and antidepressant medications. Many patients are unable to tolerate psychotherapy for PTSD and drop out of it. In addition, its effectiveness is li…
Phase 3 • Sponsor: Deakin University • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
New MS drug shows promise in reducing brain lesions
Disease control OngoingThis study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
Phase 2 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug mevidalen aims to ease Alzheimer's symptoms in 300-Person trial
Symptom relief CompletedThe main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), eve…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
AI spots baby seizures in home videos, could speed treatment
Knowledge-focused CompletedInfantile spasms are a type of seizure linked to developmental issues. Unfortunately, they are often misdiagnosed, causing delays in treatment. The purpose of this study is to develop a computer program that can reliably differentiate infantile spasms from similar, yet benign mov…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Can a protein shield your kidneys during Open-Heart surgery?
Disease control CompletedThe goal of this clinical trial is to identify the optimal dose of RMC-035 for protection of long-term renal function in adult patients undergoing cardiac surgery who are at high risk of kidney injury. It will also learn about the safety of RMC-035. The main question it aims to a…
Phase 2 • Sponsor: Guard Therapeutics AB • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
CBD oil tested for breast cancer drug side effect
Symptom relief PausedThis phase II trial tests the effectiveness of cannabidiol (CBD) plant extract (BRC-001) in improving joint stiffness and pain (arthralgia) in women with breast cancer taking aromatase inhibitors (AIs). AIs lower blood levels of estrogen in postmenopausal women to reduce breast c…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
AI eye scanner could catch glaucoma before it steals your sight
Diagnosis CompletedThe goal of this observational study is to evaluate the clinical performance of VeriSee GLC for identifying glaucoma suspects using color fundus images in adult participants. The main questions it aims to answer are: * What are the sensitivity and specificity of VeriSee GLC for …
Sponsor: Acer Medical Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
Can a mouth rinse save your taste buds during cancer treatment?
Symptom relief Recruiting nowThe purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetam…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Do screws make hip replacements last longer?
Disease control OngoingThe goal of this randomized controled trial is to compare if using of ancillary screws yields equal results as no use of ancillary screws in the ACE acetabulum cup of a total hip arthroplasty. Further, the migration of the Avanteon stem over time will be assessed. Patients includ…
Sponsor: Helse Møre og Romsdal HF • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug BL-M17D1 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in patients with locally advanced or metastatic HER2 positi…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered killer cells take on Hard-to-Treat lymphoma
Disease control OngoingOpen Label, Phase 1 study of CD19 t-haNK as a single agent and combination with rituximab in subjects with selected CD19+ and CD20+ R/R B-cell non-Hodgkin Lymphoma( NHL).
Phase 1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC